Canadian medical cannabis giant Aurora have renewed an agreement it hopes will provide access to a future UK market.
Aurora Germany, a subsidiary of the North American company, has signed a two year extension with Grow Group, a biopharmaceutical company in the UK.
The two businesses have a long-standing agreement and have recommitted to the partnership as they eye the ‘rapidly growing medical cannabis market in the UK’.
Miguel Martin, chief executive officer of Aurora Cannabis, said: “We are delighted to extend our existing strategic relationship with Grow.
“We have worked successfully with Grow and their joint venture partner, IPS, since entering the UK market.
“Renewing this agreement will help to broaden access for patients by leveraging Grow’s work educating physicians and creating awareness of medical cannabis options.
“Aurora is committed to providing access to legally produced high-quality pharmaceutical-grade medical cannabis to address the needs of the growing European medical cannabis market, made possible with our EU GMP facility, Aurora Nordic.”
Pierre van Weperen, managing director of Grow Group PLC UK & Ireland, said: “Everything we do is with the patient in mind.
“Addressing patients’ needs and broadening access to medical cannabis in the UK is at the heart of Grow’s strategy.
“Quality of products, broad range of offerings and a strong supply chain is critical to serving the UK’s fast-growing patient population.
“Partnering with companies like Aurora will continue to enable us to offer a portfolio of high-quality flowers and extracts to doctors and the patients who will benefit from them.
“Every day, these products make a difference for patients and we look forward to advancing market access together with Aurora.”
[activecampaign form=31]
